Published in Virology on August 10, 2005
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50
Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol (2010) 2.01
The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol (2006) 2.00
Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol (2007) 1.97
Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res (2009) 1.91
Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol (2010) 1.72
Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A (2009) 1.71
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc Natl Acad Sci U S A (2009) 1.48
Interplay between innate immunity and negative-strand RNA viruses: towards a rational model. Microbiol Mol Biol Rev (2011) 1.22
Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology (2007) 1.19
Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl Acad Sci U S A (2012) 1.18
The Ebola virus ribonucleoprotein complex: a novel VP30-L interaction identified. Virus Res (2008) 1.13
An upstream open reading frame modulates ebola virus polymerase translation and virus replication. PLoS Pathog (2013) 1.12
Filoviral immune evasion mechanisms. Viruses (2011) 1.10
Filovirus replication and transcription. Future Virol (2007) 1.09
An Intrinsically Disordered Peptide from Ebola Virus VP35 Controls Viral RNA Synthesis by Modulating Nucleoprotein-RNA Interactions. Cell Rep (2015) 1.07
Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol (2015) 1.07
Activation of the Antiviral Kinase PKR and Viral Countermeasures. Viruses (2009) 1.05
Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. J Mol Biol (2010) 1.04
Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. PLoS Pathog (2012) 1.03
Ebolavirus VP35 is a multifunctional virulence factor. Virulence (2010) 1.02
Assembly of the Ebola Virus Nucleoprotein from a Chaperoned VP35 Complex. Cell Rep (2015) 0.99
In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol (2014) 0.96
DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function. J Infect Dis (2011) 0.91
Correlates of immunity to filovirus infection. Viruses (2011) 0.91
The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation. J Infect Dis (2011) 0.90
Expression, purification, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.90
Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells. J Virol (2015) 0.90
The Ebola virus VP24 protein prevents hnRNP C1/C2 binding to karyopherin α1 and partially alters its nuclear import. J Infect Dis (2011) 0.89
The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals. Virology (2013) 0.89
Ebola virus VP35 interaction with dynein LC8 regulates viral RNA synthesis. J Virol (2015) 0.84
Innate immune evasion by filoviruses. Virology (2015) 0.82
Intrinsic and extrinsic negative regulators of nuclear protein transport processes. Genes Cells (2012) 0.80
Assessing the contribution of interferon antagonism to the virulence of West African Ebola viruses. Nat Commun (2015) 0.80
RNA Binding of Ebola Virus VP30 Is Essential for Activating Viral Transcription. J Virol (2016) 0.78
The Ebola Virus VP30-NP Interaction Is a Regulator of Viral RNA Synthesis. PLoS Pathog (2016) 0.77
Structure of the C-terminal domain of lettuce necrotic yellows virus phosphoprotein. J Virol (2013) 0.76
The host E3-Ubiquitin ligase TRIM6 ubiquitinates the Ebola virus VP35 protein and promotes virus replication. J Virol (2017) 0.75
Molecular dynamics exploration of the binding mechanism and properties of single-walled carbon nanotube to WT and mutant VP35 FBP region of Ebola virus. J Biol Phys (2017) 0.75
The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing. PLoS One (2017) 0.75
Predicting coiled coils from protein sequences. Science (1991) 38.18
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol (2004) 26.12
IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol (2003) 15.67
Triggering the interferon antiviral response through an IKK-related pathway. Science (2003) 11.62
Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology (1998) 9.81
Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol (2005) 9.11
The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A (2004) 7.51
Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol Cell (1998) 7.01
Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science (1990) 6.70
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A (2005) 5.64
The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A (2000) 5.46
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med (2000) 4.36
Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J Virol (2002) 4.31
Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1. Mol Cell Biol (1998) 3.70
Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol (2001) 3.65
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med (1999) 3.45
Induction of IRF-3/-7 kinase and NF-kappaB in response to double-stranded RNA and virus infection: common and unique pathways. Genes Cells (2001) 3.42
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33
Regulation of type I interferon gene expression by interferon regulatory factor-3. J Biol Chem (1998) 3.31
Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis (2003) 3.15
Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science (2001) 3.08
The V proteins of simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology (2002) 3.02
The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell (2002) 2.80
Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J Virol (2001) 2.73
Bunyamwera bunyavirus nonstructural protein NSs is a nonessential gene product that contributes to viral pathogenesis. Proc Natl Acad Sci U S A (2001) 2.63
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol (2002) 2.58
Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis (2004) 2.25
Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology (2005) 2.25
Induction of the human protein P56 by interferon, double-stranded RNA, or virus infection. Virology (2000) 2.18
Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol (2004) 2.09
Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology (2001) 1.97
Single amino acid substitution in the V protein of simian virus 5 differentiates its ability to block interferon signaling in human and murine cells. J Virol (2001) 1.95
Stabilization of short collagen-like triple helices by protein engineering. J Mol Biol (2001) 1.88
Multiple signaling pathways leading to the activation of interferon regulatory factor 3. Biochem Pharmacol (2002) 1.79
Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. Virology (1998) 1.73
Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol (1999) 1.68
STAT2 acts as a host range determinant for species-specific paramyxovirus interferon antagonism and simian virus 5 replication. J Virol (2002) 1.66
Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol (2000) 1.62
Paramyxovirus phosphoproteins form homotrimers as determined by an epitope dilution assay, via predicted coiled coils. Virology (1995) 1.51
Identification and characterization of viral antagonists of type I interferon in negative-strand RNA viruses. Curr Top Microbiol Immunol (2004) 1.47
Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol (2005) 1.44
On the domain structure and the polymerization state of the sendai virus P protein. Virology (2000) 1.29
Characterization of the oligomerization domain of the phosphoprotein of human parainfluenza virus type 3. Virology (2002) 0.94
Phosphoprotein of the rinderpest virus forms a tetramer through a coiled coil region important for biological function. A structural insight. J Biol Chem (2004) 0.88
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature (2006) 6.46
Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol (2006) 4.88
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol (2003) 4.45
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A (2002) 4.26
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2004) 4.00
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature (2008) 3.47
A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 3.44
Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog (2010) 3.08
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A (2008) 2.72
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep (2008) 2.65
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2002) 2.21
Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol (2009) 2.10
Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol (2010) 2.01
Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol (2004) 1.98
Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol (2007) 1.97
Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe (2013) 1.97
Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol (2009) 1.94
A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol (2011) 1.85
Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J Virol (2002) 1.81
Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol (2010) 1.72
Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A (2009) 1.71
Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. J Virol (2005) 1.69
Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J Immunol (2011) 1.68
Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog (2010) 1.63
Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol (2002) 1.63
Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J Virol (2006) 1.52
Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol (2009) 1.50
Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J Virol (2009) 1.50
Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med (2013) 1.49
1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis (2012) 1.41
The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation. J Virol (2004) 1.39
Capsid protein of eastern equine encephalitis virus inhibits host cell gene expression. J Virol (2007) 1.35
Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J Virol (2009) 1.31
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat Commun (2010) 1.29
Inclusion bodies are a site of ebolavirus replication. J Virol (2012) 1.29
Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol (2012) 1.20
Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog (2012) 1.19
Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology (2007) 1.19
Nipah virus sequesters inactive STAT1 in the nucleus via a P gene-encoded mechanism. J Virol (2009) 1.18
Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl Acad Sci U S A (2012) 1.18
Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol (2009) 1.16
Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol Cell Biol (2011) 1.14
Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. Int Rev Immunol (2009) 1.13
An upstream open reading frame modulates ebola virus polymerase translation and virus replication. PLoS Pathog (2013) 1.12
Chimeric influenza A viruses with a functional influenza B virus neuraminidase or hemagglutinin. J Virol (2003) 1.12
Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob Agents Chemother (2011) 1.11
Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J Virol (2011) 1.10
Filoviral immune evasion mechanisms. Viruses (2011) 1.10
Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J Virol (2010) 1.07
Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. J Mol Biol (2010) 1.04
Ebolavirus VP35 is a multifunctional virulence factor. Virulence (2010) 1.02
Nipah virus edits its P gene at high frequency to express the V and W proteins. J Virol (2009) 1.00
Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis (2011) 0.99
Vaccine potential of Nipah virus-like particles. PLoS One (2011) 0.97
Molecular mechanisms of viral inhibitors of RIG-I-like receptors. Trends Microbiol (2012) 0.96
Development of RNA aptamers targeting Ebola virus VP35. Biochemistry (2013) 0.93
A five-amino-acid deletion of the eastern equine encephalitis virus capsid protein attenuates replication in mammalian systems but not in mosquito cells. J Virol (2008) 0.92
The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antiviral Res (2012) 0.92
Sensing RNA virus infections. Nat Chem Biol (2007) 0.92
DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function. J Infect Dis (2011) 0.91
A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species- and cell-type-specific manner. J Virol (2013) 0.91
Expression, purification, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.90
The Ebola virus VP24 protein prevents hnRNP C1/C2 binding to karyopherin α1 and partially alters its nuclear import. J Infect Dis (2011) 0.89
Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol (2013) 0.86
Influenza virus infection in guinea pigs raised as livestock, Ecuador. Emerg Infect Dis (2012) 0.84
Unconventional secretion of Ebola virus matrix protein VP40. J Infect Dis (2011) 0.84
Phylogenetics and pathogenesis of early avian influenza viruses (H5N1), Nigeria. Emerg Infect Dis (2008) 0.81
Ebola virus failure to stimulate plasmacytoid dendritic cell interferon responses correlates with impaired cellular entry. J Infect Dis (2011) 0.81
Crystallization and preliminary X-ray analysis of Ebola VP35 interferon inhibitory domain mutant proteins. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 0.80
The makings of a killer. Nat Med (2002) 0.76
Influence of an additional amino group on the potency of aminoadamantanes against influenza virus A. II - Synthesis of spiropiperazines and in vitro activity against influenza A H3N2 virus. Bioorg Chem (2010) 0.76
Seroprevalence of pandemic influenza viruses, New York, New York, USA, 2004. Emerg Infect Dis (2012) 0.75